Profile

Torsten Falk

Research Professor | Research Professor, Pharmacology | Member of the Graduate Faculty | Professor, Physiological Sciences - GIDP | Professor, Neuroscience - GIDP

Collaboration(39)

Page 1 of 8

Grants(15)

Page 1 of 3

Publications(51)

Recent

The angiotensin 1-7) glycopeptide PNA5 improves cognition in a chronic progressive mouse model of Parkinson's disease through modulation of neuroinflammation.

2024

PACAP glycosides promote cell outgrowth in vitro and reduce infarct size after stroke in a preclinical model.

2024

Automated system for training and assessing reaching and grasping behaviors in rodents

2024

Differential effects of opioid receptor antagonism on the anti-dyskinetic and anti-parkinsonian effects of sub-anesthetic ketamine treatment in a preclinical model.

2024

Automated system for training and assessing reaching and grasping behaviors in rodents.

2023

Structure-Based Design of Glycosylated Oxytocin Analogues with Improved Selectivity and Antinociceptive Activity.

2023

Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion.

2023

Design and Synthesis of Novel Brain Penetrant Glycopeptide Analogues of PACAP with Neuroprotective Potential for Traumatic Brain Injury and Parkinsonism.

2022

Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine.

2021

Evaluation of microglia in a rodent model of Parkinson's disease primed with L-DOPA after sub-anesthetic ketamine treatment

2021

Profile

Torsten Falk

Collaboration(39)

Helena Morrison

Russell Witte

David Besselsen

Kurt Denninghoff

Todd Vanderah

Grants(15)

Publications(51)

The angiotensin 1-7) glycopeptide PNA5 improves cognition in a chronic progressive mouse model of Parkinson's disease through modulation of neuroinflammation.

PACAP glycosides promote cell outgrowth in vitro and reduce infarct size after stroke in a preclinical model.

Automated system for training and assessing reaching and grasping behaviors in rodents

Differential effects of opioid receptor antagonism on the anti-dyskinetic and anti-parkinsonian effects of sub-anesthetic ketamine treatment in a preclinical model.

Automated system for training and assessing reaching and grasping behaviors in rodents.

Structure-Based Design of Glycosylated Oxytocin Analogues with Improved Selectivity and Antinociceptive Activity.

Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion.

Design and Synthesis of Novel Brain Penetrant Glycopeptide Analogues of PACAP with Neuroprotective Potential for Traumatic Brain Injury and Parkinsonism.

Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine.

Evaluation of microglia in a rodent model of Parkinson's disease primed with L-DOPA after sub-anesthetic ketamine treatment